´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾ö : 2019-11-22±³À°ÀÏÀÚ : 2019-11-22
±³À°Àå¼Ò : ·Ôµ¥È£Åںλê (3Ãþ Å©¸®½ºÅ»º¼·ë)
±³À°ÁÖÁ¦ :
´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
´ã´çÀÚ : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
¿¬¶ôó : 02-794-2630
À̸ÞÀÏ :
webmaster@rheum.or.kr ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Á¤Çü¿Ü°ú, °¡Á¤ÀÇÇаú
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
ºÎ»ê±¤¿ª½Ã±³À°½Ã°£ : 10 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 60,000¿ø
ºñ°í »çÀüµî·Ïºñ ȸ¿ø Àü¹®ÀÇ, ÀüÀÓÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø 60,000¿ø, Àü°øÀÇ, °£È£»ç, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø ¿Ü 40,000¿ø, ºñȸ¿ø Àü¹®ÀÇ, ÀüÀÓÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø, ÀÇ·áÁ¾»çÀÚ 80,000¿ø, Àü°øÀÇ, °£È£»ç, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø ¿Ü 50,000¿øÇöÀåµî·Ïºñ ȸ¿ø Àü¹®ÀÇ, ÀüÀÓÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø 80,000¿ø, Àü°øÀÇ, °£È£»ç, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø ¿Ü 60,000¿ø, ºñȸ¿ø Àü¹®ÀÇ, ÀüÀÓÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø, ÀÇ·áÁ¾»çÀÚ 100,000¿ø, Àü°øÀÇ, °£È£»ç, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø ¿Ü 70,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-22 Room 1, Room 2 09:00~09:30 DAMPs in rheumatic diseases ¼Õµ¿Çö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 11-22 Room 1, Room 2 09:30~10:00 Macrophage tolerance and inflammation ¹Ú¼ºÈ£(UNIST »ý¸í°úÇкÎ)
±³À°½Ã°£ 11-22 Room 1, Room 2 10:00~10:30 Fibrosis in systemic sclerosis: basic and clinical aspects À̽±Ù(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 11-22 Room 1, Room 2 11:00~11:30 Translational Research of Rheumatoid Arthritis: From Animal Model to Human ±èÈ£¿¬(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 11-22 Room 1, Room 2 11:30~12:10 Cardiovascular Risk In Rheumatoid Arthritis: Pathogenesis, Screening, And Prevention. Jon T. Giles(Columbia Univ., USA)
±³À°½Ã°£ 11-22 Room 1, Room 2 12:10~12:50 Precision medicine in rheumatoid arthritis. Daniel Aletaha(Medical Univ. of Vienna, Austria)
±³À°½Ã°£ 11-22 Room 1 14:00~14:20 What to do after MTX failure in RA: Oral kinase inhibitors vs biologics? ¹ÚÁø±Õ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-22 Room 1 14:20~14:40 Does non-radiographic axial SpA really exist? ±è¿ë±æ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 11-22 Room 1 14:40~15:00 Rheumatoid hand surgery: Is there still a place in the era of biologics? °øÇö½Ä(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-22 Room 1 15:00~15:20 Updates in the cell-based cartilage regeneration ÀÓ±ºÀÏ(µ¿±¹ÀÇ´ë)
±³À°½Ã°£ 11-22 Room 1 16:00~16:20 What is the best target in SLE: remission or LDA? ¼ºÀ±°æ(ÇѾçÀÇ´ë)
±³À°½Ã°£ 11-22 Room 1 16:20~16:40 Treatment for refractory lupus nephritis: RTX vs multi-target therapy? ¼Ã¢Èñ(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 11-22 Room 1 16:40~17:00 Is there a place for corticosteroids in the treatment of SSc? ÀÌÀººÀ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-22 Room 1 17:00~17:20 Can we use NOACs in APS? ÀÌÁö¼ö(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 11-22 Room 2 14:00~14:20 ·ù¸¶Æ¼½º ¿Ü·¡¿¡¼ ÈçÈ÷ ½ÃÇàÇÏ´Â °Ë»çµé ±èÅÂÁ¾(Àü³²ÀÇ´ë)
±³À°½Ã°£ 11-22 Room 2 14:20~14:40 ·ù¸¶Æ¼½º ¿µ¿ª¿¡¼ ÈçÈ÷ »ç¿ëÇÏ´Â ÁøÅëÁ¦µé ±è°Ç¿ì(´ë±¸ÆÄƼ¸¶º´¿ø)
±³À°½Ã°£ 11-22 Room 2 14:40~15:00 Àü½ÅÈ«¹Ý·çǪ½ºÀÇ Áúº´È°¼ºµµ ÃøÁ¤ ±èÀ±¼º(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 11-22 Room 2 15:00~15:20 ·ù¸¶Æ¼½º°üÀý¿°ÀÇ Áúº´È°¼ºµµ ÃøÁ¤ ÃÖ¼ºÀç(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-22 Room 3 14:00~14:30 Understanding of microbiota and gut-organs axis ±è¸íÈÄ(ºÎ»ê´ëÇб³ »ý¸íÀÚ¿ø°úÇдëÇÐ)
±³À°½Ã°£ 11-22 Room 3 14:30~15:00 Microbiota in rheumatic diseases ÀÌ»óÀÏ(°æ»óÀÇ´ë)
±³À°½Ã°£ 11-22 Room 3 15:00~15:30 Analysis of Intestinal Microbiome in Rheumatoid Arthritis (RA) Patients and RA Inhibitory Effect Bifidobacterium bifidum ATT Áö±Ù¾ï(¼¿ï´ëÇб³, (ÁÖ)ºñÇǵµ ´ëÇ¥)
±³À°½Ã°£ 11-22 Room 3 16:00~16:30 Innate T cell development ÀÌÀ¯Á¤(Æ÷½ºÅØ À¶ÇÕ»ý¸í°øÇкÎ)
±³À°½Ã°£ 11-22 Room 3 16:30~17:00 Autoreactive B cell Development Çã´ë¿µ(ÀÎÁ¦ÀÇ´ë ÇغÎÇб³½Ç)
±³À°½Ã°£ 11-22 Room 3 17:00~17:30 Macrophage energetics and functions in rehumatoid arthritis ÀüÇö½Ä(°í·Á´ëÇб³ °úÇбâ¼ú´ëÇÐ »ý¸íÁ¤º¸°øÇаú)